Compositions comprising bacterial strains

Patent metadata

Field	Value
Publication number	US-11058732-B2
Application number	US-201916703980-A
Country	US
Kind code	B2
Filing date	Dec 5, 2019
Priority date	Nov 20, 2015
Publication date	Jul 13, 2021
Grant date	Jul 13, 2021

Abstract

The invention provides compositions comprising bacterial strains for treating and preventing cancer.

First claim

What is claimed is:

1. A method of increasing a level of an IL-6 or TNF-α cytokine in a subject in need thereof, comprising administering to said subject a pharmaceutical composition that comprises: (a) a bacteria strain of the species Enterococcus gallinarum that comprises a 16s rRNA gene sequence with at least 99.5% sequence identity to the polynucleotide of SEQ ID NO: 2, wherein said sequence identity is determined by the Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, and a BLOSUM matrix of 62, and (b) a prebiotic compound, wherein said administering is sufficient to increase said level of said IL-6 or TNF-α cytokine at least 100-fold relative to prior to said administering.

2. The method of claim 1 , wherein said administering is sufficient to increase said level of said IL-6 cytokine.

3. The method of claim 2 , wherein said administering is sufficient to increase said level of said IL-6 cytokine at least 600-fold, relative to prior to said administering.

4. The method of claim 1 , wherein said administering is sufficient to increase said level of said TNF-α cytokine.

5. The method of claim 4 , wherein said administering is sufficient to increase said level of said IL-6 cytokine at least 400-fold, relative to prior to said administering.

6. The method of claim 1 , wherein said pharmaceutical composition further comprises a lipopolysaccharide.

7. The method of claim 6 , wherein said administering is sufficient to increase a level of an IL-1β cytokine at least 1000-fold, relative to prior to said administering.

8. The method of claim 1 , wherein said amount of said bacteria strain comprises from about 1×10 3 to about 1×10 11 CFU/g of said bacteria strain with respect to a total weight of said pharmaceutical composition.

9. The method of claim 1 , wherein said pharmaceutical composition is formulated for oral delivery.

10. The method of claim 1 , wherein said pharmaceutical composition is formulated for delivery to an intestine of said subject.

11. The method of claim 1 , wherein said subject is human.

12. The method of claim 1 , wherein said prebiotic compound is selected from the group consisting of: a fructo-oligosaccharide, a short-chain fructo-oligosaccharide, inulin, an isomalt-oligosaccharide, a transgalacto-oligosaccharide, a pectin, a xylo-oligosaccharide, a chitosan-oligosaccharide, a beta-glucan, an arable gum modified starch, a polydextrose, a D-tagatose, an acacia fiber, carob, an oat, and a citrus fiber.

Assignees

• 4D Pharma Res Ltd

Inventors

• MULDER Imke Elisabeth
• HOLT Amy Beth
• Panzica Domenico
• Mccluskey Seanin Marie

Classifications

• A61K35/744 Primary

  Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs · CPC title

• C12N1/20 Primary

  Bacteria; Culture media therefor · CPC title

• A61K35/74 Primary

  Bacteria (therapeutic use of a bacterial protein A61K38/00) · CPC title

• A61K31/739 Primary

  Lipopolysaccharides · CPC title

• A61P37/04

  Immunostimulants · CPC title